| Citation: |
SHE Xiaowei, ZHAO Jun, XU Chun, LI Chang, DING Cheng, CHEN Jun, GONG Yongsheng. Clinical Comparison of Minimally Invasive Esophagectomy Versus Open Esophagectomy on Elderly Esophageal Carcinoma Patients (≥70 Years Old)[J]. Cancer Research on Prevention and Treatment, 2017, 44(11): 740-744. DOI: 10.3971/j.issn.1000-8578.2017.17.0666
|
To compare the clinical effect of minimally invasive esophagectomy(MIE) versus open esophagectomy (OE) on elderly esophageal carcinoma patients(≥70 years old), to provide the relevant theoretical basis for the clinical application of minimally invasive surgery on esophageal carcinoma.
We retrospectively reviewed the data of the randomly-selected elderly patients who underwent MIE or OE(each 52) in the Department of Thoracic Surgery.
The MIE group was successfully performed under thoracoscopy and laparoscopy without conversion to open esophagectomy. The mean operation time were (261.4±35.2) and (249.0±37.0)min in MIE and OE groups (P > 0.05). The intraoperative blood loss on average were respectively about (190.1±86.8) and (391.35±118.5)ml in MIE and OE groups(P < 0.05). The white blood cell(WBC), C-reactive protein(CRP) and postoperative pain evaluation were better in the MIE group than those in the OE group (P < 0.05). There was no significant difference in anastomotic fistula, recurrent laryngeal nerve injury or chylothorax between the two groups, but the incidence of pulmonary infection, respiratory failure and arrhythmia in MIE group was lower than those in OE group (P < 0.05). The hospitalization time in MIE group was less than that in OE group (P < 0.05). The patients were followed up for (22.1±11.1) months, there was no significant difference in survival time between the two groups (P=0.985).
Clinical application of MIE could significantly reduce the elderly patients' postoperative pain, systemic inflammatory response, the incidence of complications such as cardiopulmonary system, as well as the length of hospital stay. It is conducive to rapid recovery of elderly esophageal cancer patients.
| [1] |
International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012[EB/OL]. [2017-04-26]. http://globocan.iarc.fr
|
| [2] |
Liu HC, Chen YC, Chen CH, et al. Esophagectomy in elderly patients with esophageal cancer[J]. Int J Gerontol, 2015, 48(4): 121-7. http://d.wanfangdata.com.cn/OAPaper/oai_doaj-articles_9641424a53724b4c99b7dcc8a59789f2
|
| [3] |
左婷婷, 郑荣寿, 曾红梅, 等.中国食管癌发病状况与趋势分析[J].中华肿瘤杂志, 2016, 38(9): 703-8. http://d.wanfangdata.com.cn/Periodical/zhzl201609022
Zuo TT, Zheng RS, Zeng HM, et al. The incidence status and trends analysis of esophageal carcinoma in China[J]. Zhonghua Zhong Liu Za Zhi, 2016, 38(9): 703-8. http://d.wanfangdata.com.cn/Periodical/zhzl201609022
|
| [4] |
Furlong H, Bass G, Breathnach O, et al. Targeting therapy for esophageal cancer in patients aged 70 and over[J]. J Geriatr Oncol, 2013, 4 (2): 107-13. doi: 10.1016/j.jgo.2012.12.006
|
| [5] |
Tapias LF, Muniappan A, Wright CD, et al. Short and Long-Term Outcomes After Esophagectomy for Cancer in Elderly Patients[J]. Ann Thorac Surg, 2013, 95(5): 1741-8. doi: 10.1016/j.athoracsur.2013.01.084
|
| [6] |
Aridgides PD, Janik A, Bogart JA, et al. Radiotherapy for stage Ⅲ non-small-cell lung carcinoma in the elderly (age≥70 years)[J]. Clin Lung Cancer, 2013, 14(6): 674-9. doi: 10.1016/j.cllc.2013.05.001
|
| [7] |
Ohba A, Kato K, Ito Y, et al. Chemoradiation therapy with docetaxel in elderly patients with stage Ⅱ/Ⅲ esophageal cancer: A phase 2 trial[J]. Adv Radiat Oncol, 2016, 1(4): 230-6. doi: 10.1016/j.adro.2016.07.002
|
| [8] |
胡胜寿.心胸外科学[M].第1版.北京:人民卫生出版社, 2014: 107-9.
Hu SS. Thoracic and Cardiothoracic Surgey[M]. 1nd ed. Beijing: People's Medical Publishing House, 2014: 107-9.
|
| [9] |
崔玉尚, 张志庸, 阿伊都·阿布都热伊木.开胸术后早期肺功能的变化规律及影响因素分析[J].中华外科杂志, 2003, 41(12): 909-12. doi: 10.3760/j:issn:0529-5815.2003.12.008
Cui YS, Zhang ZY, Ayidu· ABDRYM, et al. Analysis of early lung function changes and influencing factors after thoracotomy[J]. Zhonghua Wai Ke Za Zhi, 2003, 41(12): 909-12. doi: 10.3760/j:issn:0529-5815.2003.12.008
|
| [10] |
RJ Battafarano. Minimally invasive esophagectomy is there an advantage?[J]. Adv Surg, 2016, 50(1): 17-28. doi: 10.1016/j.yasu.2016.03.002
|
| [11] |
F Palazzo, Rosato EL, Chaudhary A, et al. Minimally invasive esophagectomy provides significant survival advantage compared with open or hybrid esophagectomy for patients with cancers of the esophagus and gastroesophageal junction[J]. J Am Coll Surg, 2014, 220(4): 672-9. http://www.ncbi.nlm.nih.gov/pubmed/25667145
|
| [12] |
Perry Y, Fernando HC. Three-field minimally invasive esophagectomy: current results and technique[J]. J Thorac Cardiovasc Surg, 2012, 144(3): S63. doi: 10.1016/j.jtcvs.2012.06.002
|
| [13] |
Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomized controlled trial[J]. Lancet, 2012, 379(9829): 1887-92. doi: 10.1016/S0140-6736(12)60516-9
|
| [14] |
Shen Y, Zhong M, Wu W, et al. The impact of tidal volume on pulmonary complications following minimally invasive esophagectomy: A randomized and controlled study[J]. J Thorac Cardiovasc Surg, 2013, 146 (5): 1267-74. doi: 10.1016/j.jtcvs.2013.06.043
|
| [15] |
Bakhos CT, Fabian T, Oyasiji TO, et al. Impact of the surgical technique on pulmonary morbidity after esophagectomy[J]. Ann Thorac Surg, 2012, 93(1): 221-7. doi: 10.1016/j.athoracsur.2011.07.030
|
| [16] |
Yerokun BA, Sun Z, Yang CJ, et al. Minimally invasive versus open esophagectomy for esophageal cancer:a population-based analysis[J]. Ann Thorac Surg, 2016, 102(2): 416-23. doi: 10.1016/j.athoracsur.2016.02.078
|
| [17] |
Mitzman B, Lutfi W, Wang CH, et al. Minimally invasive esophagectomy provides equivalent survival to open esophagectomy:An analysis of the national cancer database[J]. Semin Thoracic Surg, 2017, 29(2): 244-53. https://www.sciencedirect.com/science/article/pii/S1043067917300904
|
| [18] |
杜泽森, 傅俊惠, 郑春鹏, 等. 胸腹腔镜联合食管癌切除术与传统开胸术式的临床对比研究[J]. 肿瘤防治研究, 2013, 41(4): 431-3. http://www.zlfzyj.com/CN/Y2014/V41/I04/431
Du ZA, Fu JH, Zheng CP, et al. Clinical comparison between minimally invasive esophagectomy and Open esophagectomy[J]. Zhong Liu Fang Zhi Yan Jiu, 2013, 41(4): 431-3. http://www.zlfzyj.com/CN/Y2014/V41/I04/431
|
| [1] | HUANG Qing, XUE Chang, HU Sheng. Development on Cancer Therapeutic Drugs Approved by FDA in 2023[J]. Cancer Research on Prevention and Treatment, 2024, 51(7): 542-545. DOI: 10.3971/j.issn.1000-8578.2024.24.0040 |
| [2] | ZHENG Yu, PAN Hongming. Progress of Targeted Therapy and Immunotherapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(4): 234-239. DOI: 10.3971/j.issn.1000-8578.2024.23.1257 |
| [3] | CHEN Jiachen, WU Tingyu, XIA Weiliang. Relationship of EGFR-TKI Targeted Therapy and Pyroptosis in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1185-1190. DOI: 10.3971/j.issn.1000-8578.2023.23.0310 |
| [4] | JI Xiaojun, ZHAO Tingli, MIAO Lei, SI Yaxuan, WU Jian, XU Dan. Progress in Development of Targeted Therapeutic Drugs for Acute Myeloid Leukemia[J]. Cancer Research on Prevention and Treatment, 2023, 50(4): 413-421. DOI: 10.3971/j.issn.1000-8578.2023.22.1056 |
| [5] | LIU Shanting, QIN Jiali, FAN Jie. Dawn of Advanced Thyroid Cancer Therapy: Targeted Therapy and Immunotherapy[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 6-11. DOI: 10.3971/j.issn.1000-8578.2023.22.0869 |
| [6] | YANG Junyuan, CAI Hongbing. Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 886-892. DOI: 10.3971/j.issn.1000-8578.2022.22.0162 |
| [7] | ZHANG Jianning, LIU Congwei. Progress of Novel Treatment Options for Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(6): 505-513. DOI: 10.3971/j.issn.1000-8578.2022.21.1514 |
| [8] | YANG Changliang, ZHANG Shuang, LIU Jingjing, LI Shuang, CHENG Ying. New Immune Checkpoint: Advances in Immunotherapy for Malignant Tumors[J]. Cancer Research on Prevention and Treatment, 2018, 45(12): 1027-1035. DOI: 10.3971/j.issn.1000-8578.2018.18.0545 |
| [9] | CHEN Rui, ZHAO Da, WANG Li'na. Mechanism and Strategies on Drug Resistance of Non-small Cell Lung Cancer to EGFR-TKI[J]. Cancer Research on Prevention and Treatment, 2017, 44(3): 225-230. DOI: 10.3971/j.issn.1000-8578.2017.03.014 |
| [10] | FENG Chengjun, LIU Xiaoke, LI Xiaoyu, WANG Yongsheng. Progress of Zoledronic Acid Combined with Targeted or Immunomodulatory Drugs in Antitumor Research[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 843-847. DOI: 10.3971/j.issn.1000-8578.2015.08.020 |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: